Harvard Bioscience, Inc. (HBIO)
0.5671
+0.01
(+1.27%)
USD |
NASDAQ |
Feb 13, 09:55
Harvard Bioscience Cash from Investing (Quarterly) : -0.348M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | -79.35M |
| Agenus, Inc. | 0.076M |
| Alnylam Pharmaceuticals, Inc. | 501.11M |
| Savara, Inc. | 21.47M |
| BioMarin Pharmaceutical, Inc. | -330.96M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 0.83M |
| Cash from Financing (Quarterly) | -1.024M |
| Free Cash Flow | 6.133M |
| Free Cash Flow Per Share (Quarterly) | 0.0108 |
| Free Cash Flow to Equity (Quarterly) | 1.011M |
| Free Cash Flow to Firm (Quarterly) | 1.531M |
| Free Cash Flow Yield | 24.38% |